FDA Latest Opioid Dilemma: Can Apadaz Stop Snorting Abuse – And Does That Even Matter?
This article was originally published in The Pink Sheet Daily
Executive Summary
KemPharm's immediate-release hydrocodone combination product has limited data about a route of abuse that FDA believes is a relatively small aspect of the epidemic.
You may also be interested in...
Keeping Track: Apadaz Approved Without Abuse-Deterrent Label, FDA Denies Translarna Appeal, And Some Priority Reviews
The latest drug development news and highlights from our US FDA Performance Tracker.
KemPharm Seeks FDA Dispute Resolution Over Apadaz's Abuse Deterrence
Sponsor hopes to demonstrate that FDA's process for reviewing extended-release abuse-deterrent opioids may not be appropriate for an immediate-release product. Apadaz would be the first immediate-release opioid with an abuse-deterrent claim if approved.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.